2019 2020 calendar gcps: free download. On-line document store on 5y1.org

ir.crinetics.com
In addition, the number of shares of common stock available for issuance under the 2018 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2018 Plan, beginning with January 1, 2019, by an amount equal to 5% of the outstanding number of shares of the Company’s common stock on December 31 ...

horizon-pharma.gcs-web.com
Amortization expense for the three months ended June 30, 2020 and 2019 was $66.7 million and $57.7 million, respectively, and was $125.3 million and $115.1 million for the six months ended June 30, 2020 and 2019, respectively. As of June 30, 2020, estimated future amortization expense was as follows (in thousands):

ir.formatherapeutics.com
In March 2019, we declared and, in March 2019 and April 2019 made, a one-time distribution in the aggregate amount of approximately $44.0 million among various of our then-shareholders as a partial return of investment capital. As of March 31, 2020, we had cash, cash equivalents and marketable securities of $142.4 million.

axsometherapeuticsinc.gcs-web.com
Interest on the 2019 Term Loan and the First Amendment to the 2019 Term Loan was payable monthly beginning April 1, 2019 and principal was due starting on October 1, 2020. In addition, the Company was required to make a final payment of $1.26 million on February 1, 2023, the maturity date of the 2019 Term Loan.

Iovance Biotherapeutics
The Company recorded a de minimis amount and $0.01 million for the three months ended September 30, 2020 and 2019, respectively, and a de minimis amount and $0.02 million for the nine months ended September 30, 2020 and 2019, respectively, as research and development expenses in connection with the Second Moffit License. M.D. Anderson Cancer Center

ir.formatherapeutics.com
UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. WASHINGTON, DC 20549. FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19

Investor Relations | Nurix Therapeutics, Inc.
On December 1, 2019, we adopted Accounting Standards Update No. 2014-09 (Topic 606), Revenue from Contracts with Customers. As such, the unaudited interim condensed financial statements and therefore the summary financial data as of May 31, 2020 and for the six months then ended presented below were prepared on a basis consistent with Topic 606.

[DOCX File]2005-2006 Gwinnett Student Leadership Team Application - GCPS
https://info.5y1.org/2019-2020-calendar-gcps_1_46c6f3.html
To release the Gwinnett Student Leadership Team (GSLT), and the GSLT Board of Directors and Gwinnett County Public Schools, their officers, employees, and agents from any and all liability, loss, damage, costs, claims, or courses of action including, but not limited to, all bodily injuries and property damages arising out of the sole negligence of Gwinnett Student Leadership Team.

Precision BioSciences
The 2019 Plan provides for an annual increase to the number of shares of common stock available for issuance on the first day of each calendar year beginning January 1, 2020 and ending on and including January 1, 2029 by an amount equal to the lesser of (i) 4% of the aggregate number of shares of common stock outstanding on the final day of the ...

[DOC File]PRINCIPAL’S MESSAGE
https://info.5y1.org/2019-2020-calendar-gcps_1_32da50.html
2019-2020. PRINCIPAL’S MESSAGE. Dear Parents/Guardians and Students: It is my pleasure to welcome you to Eastern Elementary/Middle School. The faculty and staff join me in saying we’re happy to have you as part of the Eastern family. We hope this will be a successful academic year for your child.

ir.cytomx.com
UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. WASHINGTON, D.C. 20549. FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF

Investor and Media | Keros Therapeutics
The Company recognized $0 and $2.5 million of revenue in its condensed consolidated statements of operations for the three months ended June 30, 2020 and 2019, respectively, and $0 and $5.0 million for the six months ended June 30, 2020 and 2019, respectively, related to the Novo Agreement.

ir.mirumpharma.com
In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 5% of the outstanding number of shares of the Company ...

scpharmaceuticalsinc.gcs-web.com
As of September 30, 2020, unpaid borrowings under the 2019 Loan Agreement totaled $20.0 million. For the three and nine months ended September 30, 2020, the Company recorded $94,000 and $260,000, respectively, related to the amortization of debt discount associated with the 2019 Loan Agreement.

Iovance Biotherapeutics
The Company recorded research and development costs of $0.1 and $0.2 million for the three months ended June 30, 2020 and 2019, respectively, and $0.3 million and $0.5 million for the six months ended June 30, 2020 and 2019, respectively, in connection with the research collaboration and clinical grant agreements with Moffitt.

2019 2020 calendar gcps